Biophagy’s anti-viral program with Dr. Bradfute (UNM) is being extended to include zika and hanta virusesBy jordan|2022-02-01T19:12:15+00:00February 1, 2022|Categories: 2022-announcements|0 CommentsRead More
Biophagy is awarded a STEP grant through the NM Department of Economic Development for upgrading its website. This will help attract international partners and collaborators.By jordan|2022-03-22T20:32:58+00:00February 1, 2022|Categories: 2021-announcements|0 CommentsRead More
Biophagy initiates a collaboration with Dr. Ramesh Jha, Los Alamos National Laboratories, to study its antiviral compounds using molecular docking. This will help determine ligand affinity and specificity for use in lead development.By jordan|2022-03-22T20:33:09+00:00February 1, 2022|Categories: 2021-announcements|0 CommentsRead More
Biophagy announces the granting of a USPTO composition-of-matter patent for several compounds in its BPY-100 series. These proprietary molecules have shown activity in assays related to tuberculosis, covid-19, and neurodegenerative disorders.By jordan|2022-03-22T20:35:45+00:00February 1, 2022|Categories: 2021-announcements|0 CommentsRead More
Biophagy presents “Examining the Potency of Potential Autophagy Inducing Drugs,” at a UNM Discovery SymposiumBy jordan|2022-03-22T20:33:35+00:00February 1, 2022|Categories: 2020-announcements|0 CommentsRead More
Biophagy initiates a new program to study its proprietary compounds in SARS-CoV-2 (covid-19). These studies will be conducted by Dr. Steven Bradfute at UNM.By jordan|2022-03-22T20:33:48+00:00February 1, 2022|Categories: 2020-announcements|0 CommentsRead More